As accessible health care providers, pharmacists can raise awareness about the proper use of OTC blood glucose meters and continuous glucose monitoring devices.
|Articles|August 5, 2013
- July/August 2013
- Volume 4
- Issue 4
Young Infants at Greatest Risk for RSV Hospitalization
Advertisement
Infants younger than 2 months are at the greatest risk of being hospitalized for respiratory syncytial virus (RSV), according to the results of a study published online on July 22, 2013, in Pediatrics. To clarify conflicting estimates of RSV hospitalization rates found in previous studies, the researchers analyzed data from a prospective, population-based study of children younger than 2 years hospitalized for acute respiratory illness from October through March between 2000 and 2005.
A total of 2149 children were enrolled in the study and 26% were infected with RSV. The average hospitalization rate for RSV in all children younger than 2 years was 5.2 per 1000. Infants at 1 month of age had a rate of hospitalization for RSV of 25.9 per 1000, the highest found in the study. Infants 2 months and younger had an RSV hospitalization rate of 17.9 per 1000 and made up 44% of all children hospitalized with RSV. The RSV hospitalization rate for children in this age group was approximately twice that of children aged 3 to 5 months and more than 4 times that of those aged 6 to 11 months. In addition, the RSV hospitalization rate for very preterm infants was 3 times that of term infants.
Articles in this issue
about 13 years ago
September-October 2013 Meetingsabout 13 years ago
Growth Hormone Therapy: A Specialty Pharmacy Overviewabout 13 years ago
Many Antibody-Positive Patients Are Never HCV RNA Testedabout 13 years ago
HCV and OBI Co-Infections May Increase Poor Outcomesabout 13 years ago
RSV Infections in Infancy Linked to Wheezing in Childhoodabout 13 years ago
Triple Therapy May Cause More Adverse Reactions in HCV Patientsabout 13 years ago
Adding a Specialty Pharmacy to Your Retail Brandabout 13 years ago
How Smartphones Will Transform Your Patient Relationshipsabout 13 years ago
Who Really Knows Best?Newsletter
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.
SubscribeAdvertisement
Related to this article
Growing evidence points to gallstones and cholecystitis as an underrecognized risk of GLP-1 RA therapy—pharmacists are well positioned to catch it early.
As earning years peak, so do spending and responsibility—here’s where midcareer pharmacists should focus their financial decision-making.
Despite the controversy surrounding mRNA's role in the COVID-19 response, the technology's broader promise—to prevent, treat, and even cure a host of diseases—is coming into focus.
Advertisement
Advertisement